Benralizumab for the Prevention of COPD Exacerbations | Zendy

Gerard J. Criner | Zendy; Bartolomé R. Celli | Zendy; Christopher E. Brightling | Zendy; Àlvar Agustí | Zendy; Alberto Papi | Zendy; Dave Singh | Zendy; Don D. Sin | Zendy; Claus Vogelmeier | Zendy; Frank C. Sciurba | Zendy; Mona Bafadhel | Zendy; Vibeke Backer | Zendy; Motokazu Kato | Zendy; Alejandra RamírezVenegas | Zendy; Yu-Feng Wei | Zendy; Leif Bjermer | Zendy; Vivian H. Shih | Zendy; Maria Jison | Zendy; Sean O’Quinn | Zendy; Natalya Makulova | Zendy; Paul Newbold | Zendy; Mitchell Goldman | Zendy; Ubaldo J. Martin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Benralizumab for the Prevention of COPD Exacerbations

Author(s) -

Gerard J. Criner,

Bartolomé R. Celli,

Christopher E. Brightling,

Àlvar Agustí,

Alberto Papi,

Dave Singh,

Don D. Sin,

Claus Vogelmeier,

Frank C. Sciurba,

Mona Bafadhel,

Vibeke Backer,

Motokazu Kato,

Alejandra RamírezVenegas,

Yu-Feng Wei,

Leif Bjermer,

Vivian H. Shih,

Maria Jison,

Sean O’Quinn,

Natalya Makulova,

Paul Newbold,

Mitchell Goldman,

Ubaldo J. Martin

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1905248

Subject(s) - benralizumab , copd , medicine , pulmonary disease , monoclonal antibody , monoclonal , intensive care medicine , immunology , antibody , asthma , eosinophil , mepolizumab

The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research